**Name of Journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 49852

**Manuscript Type:** CASE REPORT

**Recognizable type of pituitary, heart, kidney and skeletal dysplasia mostly caused by *SEMA3A* mutation: A case report**

Hu F *et al*. A case report about *SEMA3A* mutation

Fang Hu, Liao Sun

**Fang Hu,** **Liao Sun,** Department of Endocrinology and Metabolism, Fifth Affiliated Hospital Sun Yat-Sen University, Sun Yat-Sen University, Zhuhai 519000, Guangdong Province, China

**ORCID number:** Fang Hu (0000-0002-6610-6495); Liao Sun (0000-0002-1798-0944).

**Author contributions:** All authors collected and analyzed the patient’s clinical data; Hu F wrote the manuscript and Sun L revised the manuscript.

**Informed consent statement:** The patient provided written informed consent to the publication of this case report.

**Conflict-of-interest statement:** The authors declare that they have no conflicts of interest.

**CARE Checklist (2016) statement:** The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Manuscript source:** Unsolicited manuscript

**Corresponding author:** **Liao Sun, PhD, Chief Doctor,** Department of Endocrinology and Metabolism, Fifth Affiliated Hospital Sun Yat-Sen University, Sun Yat-Sen University, Meihuadong Road 52, Zhuhai 519000, Guangdong Province, China. sunliao@mail.sysu.edu.cn

**Telephone:** +86-756-2528741

**Fax:** +86-756-2528741

**Received:** June 25, 2019

**Peer-review started:** June 27, 2019

**First decision:** July 31, 2019

**Revised:** August 29, 2019

**Accepted:** September 11, 2019

**Article in press:** September 11, 2019

**Published online:** October 26, 2019

**Abstract**

***BACKGROUND***

The *SEMA3A* gene, which is located at 7q21.11, is involved in hypothalamic neuron migration, heart development, kidney development, and skeleton metabolism. Mutation of the *SEMA3A* gene is associated with Kallmann syndrome 16 with or without a normal sense of smell. In addition, two case reports showed that mutation of the *SEMA3A* gene could cause short stature, low gonadotropin, hypogonadism, thoracic deformity, a high scapula, rib and lower limb deformity, facial deformity (long face, epicanthic folds, backwards ears), and arterial malformation.

***CASE SUMMARY***

We reported the case of a 26-year-old Chinese man who was admitted because of short stature. Physical examination showed that he had many abnormal symptoms, including a short neck, facial moles, knee valgus, transverse palm, continuous grade 5/6 murmurs in the pulmonary auscultation area, no whiskers, or pubic hair, no Adam’s apple, short penis and cryptorchidism. Radiological examination showed pituitary, gonad, heart, kidney and skeletal dysplasia. The laboratory tests revealed low growth hormone, luteinizing hormone, follicle-stimulating hormone, testosterone and estrogen. Clinical whole-exome detection showed that our patient, unlike previously reported patients, has a new *SEMA3A* gene mutation (c.950A>G). Now, his height has increased by 3 cm. In addition, he has a good appetite and reduced subcutaneous fat over 3 mo of recombinant human growth hormone injections therapy. Unfortunately, he refuses further treatment about gonad.

***CONCLUSION***

Patients who come to a hospital because of their short stature must undergo gene detection if they have other simultaneous abnormal phenotypes.

**Key words:** Pituitary dysplasia; Heart dysplasia; Kidney dysplasia; Short stature; Cryptorchidism; *SEMA3A*; Case report

**© The Author(s) 2019.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** The *SEMA3A* gene is involved in hypothalamic neuron migration, heart development, kidney development, and skeleton metabolism. Mutation of the *SEMA3A* gene was associated with short stature, low gonadotropin, hypogonadism, thoracic deformity, a high scapula, rib and lower limb deformity, facial deformity (long face, epicanthic folds, backwards ears), and arterial malformation in cases reported before. Here, we report a patient who exhibited pituitary, heart, kidney and skeletal dysplasia caused by new mutation of the *SEMA3A* gene (c.950A>G).

**Citation:** Hu F, Sun L. Recognizable type of pituitary, heart, kidney and skeletal dysplasia mostly caused by *SEMA3A* mutation: A case report. *World J Clin Cases* 2019; 7(20): 3310-3315

**URL:** https://www.wjgnet.com/2307-8960/full/v7/i20/3310.htm

**DOI:** https://dx.doi.org/10.12998/wjcc.v7.i20.3310

**INTRODUCTION**

The *SEMA3A* gene is located at 7q21.11 and has a length of 496947 bp. *SEMA3A* is a member of the [semaphorin](https://en.wikipedia.org/wiki/Semaphorin) family and encodes a protein with an Ig-like [C2-type](https://en.wikipedia.org/wiki/Immunoglobulin_C2-set_domain) (immunoglobulin-like) domain, a [PSI domain](https://en.wikipedia.org/w/index.php?title=PSI_domain&action=edit&redlink=1" \o "PSI domain (page does not exist)) and a [sema domain](https://en.wikipedia.org/wiki/Sema_domain) called semaphorin-3A. Semaphorin-3A is important in the development and migration of hypothalamic neurons. It is secreted by neurons and their surrounding tissue and guides migrating cells to their correct destination following very precise paths, sends out axons, and reacts to specific chemical environments. In addition, as a dual regulator of osteoclasts and osteoblasts, semaphorin 3A is involved in the balance of bone homeostasis by the *SEMA3A*/*NRP1* axis and the Wnt/β-catenin signaling pathway[1]*.* Semaphorins are needed in kidney development because they regulate ureteric bud branching, vascular morphogenesis, and podocyte-endothelial crosstalk[2]*. SEMA3A*-knockout mice exhibited an abnormal electrocardiograph pattern and were prone to ventricular arrhythmias and sudden cardiac death[3]. Therefore, *SEMA3A* is important in maintaining normal heart function.

*SEMA3A* mutations often appear in patients with Kallmann syndrome[4]*.* In addition, patients with mutation of the *SEMA3A* gene exhibiting short stature, low gonadotropin, hypogonadism, thoracic deformity, high scapula, rib and lower limb deformity, facial deformity (long face, epicanthic folds, backwards ears), arterial malformation, and a normal sense of smell have been reported[5]. We report a patient who exhibited pituitary, heart, kidney and skeletal dysplasia caused by new mutation of the *SEMA3A* gene.

**CASE PRESENTATION**

***Chief complaints***

A 26-year-old Chinese man complained of short stature.

***History of present illness***

The 26-year-old patient, who was his parents’ first child, was 50 cm in length and weighed 3.3 kg when he was born at 40 wk of gestation. His growth rate gradually slowed down beginning at the age of 12. Now, he is 133 cm tall (< -2.0 SD) with a 65 cm long upper half and 68 cm long lower half and weighs 35 kg (< -2.0 SD), with 130 cm finger spacing.

***History of past illness***

No disease in the past.

***Personal and family history***

His sister is of normal height and physical development. The patient was born normally without ischemia and hypoxia. His mother’s height is 156 cm, and his father’s height is 155 cm. The predicted height of the boy was calculated to be below the mid-parental height of 162 cm.

***Physical examination upon admission***

His abnormal symptoms are a short neck; facial moles; knee valgus; transverse palm; continuous grade 5/6 murmurs in the pulmonary auscultation area; no whiskers, or pubic hair; no Adam’s apple; a penis length of approximately 2 cm; a penis circumference of 3 cm and cryptorchidism (Figure 1A).

***Laboratory examinations***

The patient’s liver and kidney function, cortisol rhythm and thyroid function were normal. He completely lacked growth hormone, as shown through hypoglycemia challenge, a levodopa test and IGF-1 determination. His 25-hydroxyvitamin D was 11.3 ng/mL (low). Sex hormone assessment showed that the levels of luteinizing hormone (LH), follicle-stimulating hormone, testosterone and estrogen were all below normal. The peak LH level in a GnRH excitation test was 1.92 nmol/L (< 5 nmol/L). The peak testosterone level in a delayed human chorionic gonadotropin excitation test was 0.91 ng/mL (< 10 ng/mL). Conventional karyotyping after GTG-banding at a 500-band resolution showed a normal male karyotype (46, XY). Chromosomal microarray analysis showed no abnormalities.

Written informed consent for clinical whole-exome detection was obtained from the patient. All of the 3583 genes identified by the OMIM database were identified by high-throughput sequencing. Clinical whole-exome detection was offered by BGI in Shenzhen, Guangdong Province.

The results of clinical whole-exome detection are shown in Table 1. The diseases related to the *LHCGR, HSPG2,* and *PKDIL1* genes were autosomal recessive. *ANCA* gene-related exfoliative osteochondritis, short statue, early onset arthritis and vertebral hypoplasia exhibited autosomal dominant inheritance. *SEMA3A* gene-related hypogonadotropic hypogonadism with or without olfactory loss exhibited autosomal dominant inheritance.

***Imaging examinations***

His bone age was 15 years old (Figure 1E). Dual-energy X-ray bone density assessment showed that the T (lumbar spine) was -5.3 SD below the mean and T (left hip joint) was -2.4 SD below the mean. Pelvic magnetic resonance imaging (MRI) (Figure 1C, D) showed the following: (A) pelvic genitourinary dysplasia, in which (1) the prostate and bilateral seminal vesicles were not clearly shown; (2) the bilateral groin had soft tissue nodules and testicular hypoplasia; and (3) penile dysplasia was observed; and (B) a pelvic bone that was not closed. In addition, abdominal ultrasound suggested left renal hypoplasia. Cardiac ultrasound suggested aortic dysplasia with moderate reflux. Pituitary MRI suggested pituitary dysplasia (Figure 1B).

**FINAL DIAGNOSIS**

*LHCGR, HSPG2,* *PKDIL1*, *ANCA* and *SEMA3A* are all heterozygous mutation. So *ANCA and SEMA3A* gene mutations might be related to the symptom shown by our patient. However, *ANCA* gene mutation could not cause the previously reported gonadal and cardiac dysplasia. Therefore, we focused on *SEMA3A* as the pathogenic gene. So final diagnosis is *SEMA3A* mutation, growth hormone deficiency, short stature, hypogonadotropic hypogonadism, heart dysplasia, kidney dysplasia and skeletal dysplasia.

**TREATMENT**

The patient was treated with recombinant human growth hormone injections (0.15 U/kg, GenSci, Changchun, Jilin Province). He refuses further treatment about gonad.

**OUTCOME AND FOLLOW-UP**

Now, his height has increased by 3 cm. In addition, he has a good appetite and reduced subcutaneous fat over 3 mo of recombinant human growth hormone injections therapy. We will continue to observe his height, bone density and gonads.

**DISCUSSION**

Two similar case reports have been published before. The *SEMA3A* genotype of the first case reported in 2013 included a compound-heterozygous de novo in-frame mutation in exon 9 (c.945\_949delinsTACATCTTCTAATG; p. Phe316\_Lys317-delinsThrSerSerAsnGlu), a 150-kb deletion, the retention of intron 8, and a premature stop codon after 348 amino acids[6]*.* The *SEMA3A* genotype of the second case reported in 2018 included a homozygous c.607C>T [p.(Arg203\*)] mutation in exon 6[5]. All patients not only exhibited short statue, facial dysmorphism and skeletal system anomalies but also had cardiovascular, urogenital, hearing, olfactory, visual, motor development and cognitive development defects. There were some differences between our patient and the two patients presented previously (Table 2). First, the *SEMA3A* genotype in our patient is c.950A>G. Second, examination of our patient showed a complete lack of growth hormone, but this was not mentioned during the examination of the other two patients. Our patient’s short statue was perhaps caused by not only a lack of growth hormone but also vitamin D deficiency. Third, our patient has normal cognitive function and works in an electrical factory. Finally, he has kidney hypoplasia. Semaphorins are needed in kidney development because they regulate ureteric bud branching, vascular morphogenesis, and podocyte-endothelial crosstalk[5]*.* Thus, *SEMA3A* gene mutation might result in kidney hypoplasia. In contrast, *SEMA3A* overexpression could promote foot process effacement, glomerular basement lamination, and endothelial damage in vivo and disrupt autonomous podocyte shape by downregulating nephrin and inhibiting αvβ3 integrin[7]. Excess *SEMA3A* also promoted severe diabetic nephropathy[8].No genes related to pituitary dysplasia were discovered in whole gene exome detection. Pituitary dysplasia might occur mainly because of defective hypothalamic neurons.

**CONCLUSION**

At present, short stature gets more and more attention. But we should make a clear diagnosis through gene detection if they have other simultaneous abnormal phenotypes.

**REFERENCES**

1 **Tse MT**. Bone diseases: SEMA3A strikes a balance in bone homeostasis. *Nat Rev Drug Discov* 2012; **11**: 442 [PMID: 22596250 DOI: 10.1038/nrd3759]

2 **Reidy K**, Tufro A. Semaphorins in kidney development and disease: modulators of ureteric bud branching, vascular morphogenesis, and podocyte-endothelial crosstalk. *Pediatr Nephrol* 2011; **26**: 1407-1412 [PMID: 21336944 DOI: 10.1007/s00467-011-1769-1]

3 **Boczek N J,** Ye D, Johnson E K, Wang W, Crotti L, Tester D J, Dagradi F, Mizusawa Y, Torchio M, Alders M, Giudicessi J R, Wilde A A M, Schwartz P J, Nerbonne J M, Ackerman M J. Characterization of *SEMA3A*-Encoded Semaphorin as a Naturally Occurring Kv 4.3 Protein Inhibitor and its Contribution to Brugada Syndrome. *Circ Res* 2014; **115**: 460-469 [DOI: 10.1161/CIRCRESAHA.115.303657]

4 **Hanchate NK**, Giacobini P, Lhuillier P, Parkash J, Espy C, Fouveaut C, Leroy C, Baron S, Campagne C, Vanacker C, Collier F, Cruaud C, Meyer V, García-Piñero A, Dewailly D, Cortet-Rudelli C, Gersak K, Metz C, Chabrier G, Pugeat M, Young J, Hardelin JP, Prevot V, Dodé C. SEMA3A, a gene involved in axonal pathfinding, is mutated in patients with Kallmann syndrome. *PLoS Genet* 2012; **8**: e1002896 [PMID: 22927827 DOI: 10.1371/journal.pgen.1002896]

5 **Baumann M**, Steichen-Gersdorf E, Krabichler B, Müller T, Janecke AR. A recognizable type of syndromic short stature with arthrogryposis caused by bi-allelic SEMA3A loss-of-function variants. *Clin Genet* 2017; **92**: 86-90 [PMID: 28075028 DOI: 10.1111/cge.12967]

6 **Hofmann K**, Zweier M, Sticht H, Zweier C, Wittmann W, Hoyer J, Uebe S, van Haeringen A, Thiel CT, Ekici AB, Reis A, Rauch A. Biallelic SEMA3A defects cause a novel type of syndromic short stature. *Am J Med Genet A* 2013; **161A**: 2880-2889 [PMID: 24124006 DOI: 10.1002/ajmg.a.36250]

7 **Mohamed R**, Ranganathan P, Jayakumar C, Nauta FL, Gansevoort RT, Weintraub NL, Brands M, Ramesh G. Urinary semaphorin 3A correlates with diabetic proteinuria and mediates diabetic nephropathy and associated inflammation in mice. *J Mol Med (Berl)* 2014; **92**: 1245-1256 [PMID: 25249008 DOI: 10.1007/s00109-014-1209-3]

8 **Liu DM**, Lu N, Zhao L, Zhang MJ, Tao B, Xuan Y, Sun LH, Zhao HY, Wang WQ, Liu JM, Ning G. Serum Sema3A is in a weak positive association with bone formation marker osteocalcin but not related to bone mineral densities in postmenopausal women. *J Clin Endocrinol Metab* 2014; **99**: E2504-E2509 [PMID: 25050899 DOI: 10.1210/jc.2014-1443]

**P-Reviewer:** Papachristou G **S-Editor:** Dou Y **L-Editor:** Ma JY **E-Editor:** Qi LL

**Specialty type:** Medicine, Research and Experimental

**Country of origin:** China

**Peer-review report classification**

Grade A (Excellent): 0

Grade B (Very good): 0

Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0

**Figure 1 Clinical findings and radiographic abnormalities in a patient with a heterozygous *SEMA3A* gene mutation (c.950A>G).** The patient was 26 years old. A: He exhibited a short neck; facial moles; knee valgus; transverse palm; continuous grade 5/6 murmurs in the pulmonary auscultation area; no whiskers,or pubic hair; no Adam’s apple; short penis and cryptorchidism; B: Pituitary magnetic resonance imaging (MRI) showed pituitary dysplasia; C, D: Pelvic MRI showed the following: (1) pelvic genitourinary dysplasia, in which (1) the prostate and bilateral seminal vesicles were not clearly shown; (2) the bilateral groin had soft tissue nodules and testicular hypoplasia; and (3) penile dysplasia was observed, and (B) a pelvic bone that was not closed; E: Left wrist orthotopic X-ray (bone age of 15 years).

**Table 1 Clinical whole-exome detection results**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Gene** | **Sequence** | **Nucleotide change/mutation** | **Amino acid change** | **Gene subregion** | **Heterozygous** | **Chromosome location** | **Variant type** |
| *ACAN* | NM\_013227.3 | c.6798G>A | p.Pro22666= | EX12 | Heterozygous | Chr15: 89402614 | VUS |
| *LHCGR* | NM\_000233.3 | c.911G>A | p.Cys304Tyr | EX10 | Heterozygous | Chr2: 48921399 | VUS |
| *HSPG2* | NM\_005529.5 | c.1216C>T | p.Pro406Ser | EX11 | Heterozygous | Chr1: 22211645 | VUS |
| *PKD1L1* | NM\_138295.3 | c.2842T>G | p.Phe948Val | EX18 | Heterozygous | Chr7: 47925647 | VUS |
| *SEMA3A* | NM\_006080.2 | c.950A>G | p.Lys317Arg | EX9 | Heterozygous | Chr7: 83640383 | VUS |

VUS: Variant uncertain significace.

**Table 2 Summary of patients’ clinical presentations and comparison to the published patients**

|  |  |  |  |
| --- | --- | --- | --- |
| **Ethnicity** | **Patient 1** | **Patient 2** | **Patient 3** |
| **Asian** | **Turkish** | **Southern German**  |
| Mutation | c.950A>G (p.Lys317Arg) in exon 9, heterozygous | c.607C>T [p.(Arg203\*)] in exon 6, homozygous | c.945\_949delinsTACATCTTCTAATG; p.Phe316\_Lys317-; delinsThrSerSerAsnGlu in exon 9, de novo, in-frame; 150-kb deletion, intron-8 retention, premature stop codon after 348; amino acids, compound-heterozygous |
| Gender | Male | Male | Male |
| Gestational age (wk) | 40 | 41 | 37 |
| Age at examination | 26 | 8 | 6  |
| Birth weight and length | Weight: unknown; Length: unknown | Weight: 3720 g (P50-P75; 0.19 SDS); Length: 50 cm (P10-25; -1.25 SDS) | Weight: 2910 g (P25-P50; -0.92 SDS); Length: 48 cm (P10-P25; -0.43 SDS) |
| Mother’s and father’s heights | 156 cm, 155 cm | 154 cm, 174 cm | 159 cm, 174 cm |
| Short statue | + | + | + |
| Facial dysmorphism | Facial moles, transverse palm | Long face; epicanthic folds; mildly low-set, backwards; rotated ear; bilateral retrolobular notches; long philtrum | Long face; epicanthic folds; mildly low-set, backwards, rotated ear; dolichocephaly; prominent forehead; broad nasal root; rounded nasal tip; long philtrum; thin lips; high palate; crossbite with crowded teeth |
| Skeletal system | Short neck, knee valgus | High-positioned scapulae, lateral clavicle hook, restricted mobility of the shoulder joints, arched rib deformation, mild upper thoracic; scoliosis, widely spaced nipples, camptodactyly of the second and third fingers, flexion contracture of the right knee with patellar luxation | Sloping shoulders, broad and asymmetric thorax, flattened vertebrae in the upper thoracic region, mild funnel chest, kyphosis, hyperlordosis, widely spaced nipples, camptodactyly, of the third left finger,relatively large first toe |
| Cardiovascular | Aortic dysplasia with moderate reflux | Arteria lusoria | Patent foramen ovale, nearly closed with 6 yr |
| Urogenital | No prostate, bilateral seminal vesicles, testicular hypoplasia and cryptorchidism, micropenis | Micropenis | Micropenis |
| Hearing | Normal | Mild conductive hearing impairment | Susceptible to upper airway and middle ear infections until 2 yr of age |
| Olfaction | Normal | Normal | Normal |
| Vision | Normal | Myopia | Hyperopia |
| Motor development | Normal | Delayed, walking independently at 3.8 yr | Delayed, walking independently at 21 mo |
| Cognitive development | Normal | Reduced performance and verbal score with a full scale IQ of 55 (at 6 yr) | Average performance and full scale IQ, verbal IQ in the lower average; range (at 5 yr) |
| Kidney | Hypoplasia | Normal | Normal |
| Growth hormone | Lacking | Unknown | Unknown |
| Sex hormone | Lacking | Unknown | Unknown |

IQ: Intelligence quotient.